^
    2ms
    FREEDOM: Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Harbin Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • docetaxel • albumin-bound paclitaxel • irinotecan • Fruzaqla (fruquintinib)
    2ms
    Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Sichuan University
    New P2 trial
    |
    Tyvyt (sintilimab) • oxaliplatin • Fruzaqla (fruquintinib)
    3ms
    A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland (clinicaltrials.gov)
    P=N/A, N=110, Not yet recruiting, Takeda
    New trial • Real-world evidence
    |
    Fruzaqla (fruquintinib)
    3ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=404, Completed, BeOne Medicines | Active, not recruiting --> Completed
    Trial completion
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • alcestobart (LBL-007) • BGB-15025 • BGB-A445 • surzebiclimab (BGB-A425)
    3ms
    A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    |
    capecitabine • oxaliplatin • Fruzaqla (fruquintinib) • Hetronifly (serplulimab)
    3ms
    A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    Fruzaqla (fruquintinib)
    3ms
    Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China. (PubMed, Future Oncol)
    Monotherapy subgroup reported the lowest incidence of TEAEs (74.47%) and grade ≥3 TEAEs (23.94%), while the fruquintinib + chemotherapy subgroup reported the highest incidence (85.52%). Fruquintinib combination therapy demonstrated a satisfactory safety profile within the treatment groups.
    Journal • Real-world evidence
    |
    FLT1 (Fms-related tyrosine kinase 1)
    |
    Fruzaqla (fruquintinib)
    3ms
    COFRUQ: Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Fruzaqla (fruquintinib)
    3ms
    IGNITE-CRC: A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=68, Not yet recruiting, National Cancer Center Hospital East
    New P1/2 trial • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Fruzaqla (fruquintinib) • S-531011
    3ms
    CTMP-REV7 axis modulates MHC-I antigen presentation via CDK1-AKT crosstalk in MSI-L/MSS colorectal cancer. (PubMed, Cell Oncol (Dordr))
    We delineate that CTMP drives immune evasion in MSI-L/MSS CRC through a novel CTMP-REV7-CDK1 axis that couples metabolic reprogramming, cell cycle control, and MHC-I antigen presentation, with AKT signaling serving as a critical crosstalk node. These findings implicate this integrated axis as a therapeutic target to restore tumor immunogenicity and overcome immunotherapy resistance in immunologically "cold" MSI-L/MSS colorectal cancer.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • HLA-B (Major Histocompatibility Complex, Class I, B) • CDK1 (Cyclin-dependent kinase 1) • CGAS (Cyclic GMP-AMP Synthase)
    |
    TMB-L
    |
    Fruzaqla (fruquintinib)
    3ms
    Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective. (PubMed, Clin Colorectal Cancer)
    Agents such as trifluridine/tipiracil, regorafenib, and fruquintinib offer additional benefit in heavily pretreated mCRC. Anticipated paradigm shifts with novel agents may further refine management strategies and improve outcomes for these patients. As the landscape evolves, ongoing multidisciplinary collaboration will be essential in optimizing both patient selection and therapy sequencing as new options become available.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    3ms
    A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Suspended, Shanghai 6th People's Hospital | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial suspension • Trial primary completion date
    |
    Fruzaqla (fruquintinib) • Enweida (envafolimab)